Sensilia Laboratory is a French, family-owned and independent laboratory based in Gironde, France. Since 2019, we have been researching and manufacturing healthy, innovative wellness products.
Need help?
+33 5 54 54 00 79
support@sensilia.com
Secure payments on sensilia.com with
Made by Fifty Seven & Ocean Vert Distribution
Sensilia/Pernixol® all rights reserved
Glucosamine & Chondroitin for Dog Arthritis: Do They Work?
Glucosamine and Chondroitin for Dog Arthritis: Do They Really Work?
Do glucosamine and chondroitin really help dogs with arthritis? We break down forms, absorption, clinical trials, and better-evidenced joint support options.
For more than twenty years, glucosamine and chondroitin have been used to support dogs' joints. Their popularity rests on an appealing theory: protect and nourish cartilage. But what do veterinary studies really show? The gap between popular enthusiasm and clinical evidence raises questions, and fuels debate about their place alongside newer alternatives.
Glucosamine and chondroitin: Definition and action on joints
Glucosamine: a cartilage precursor
Glucosamine is an amino sugar naturally present in the body, notably in synovial fluid and cartilage. It is essential for the production of glycosaminoglycans (GAGs) and proteoglycans, which are the major components of the cartilaginous matrix.
In theory, glucosamine supplementation would:
provide the elements needed for the productionof cartilage
stimulate chondrocytes (cartilage cells) to produce more matrix,
and reduce certain intra-articular inflammatory processes.
It is this precursor role that justified its clinical exploration for more than 20 years in humans, and then in dogs.
Chondroitin: a structural glycosaminoglycan
Chondroitin sulfate is a sulfated glycosaminoglycan, abundant in cartilage. It contributes to water retention, which gives cartilage its flexibility and mechanical resistance.
Its presumed mechanisms include:
protection of cartilage by inhibiting certain destructive enzymes (metalloproteinases),
a mild anti-inflammatory action,
and a role in hydration of the cartilaginous matrix.
Different forms and bioavailability
Glucosamine salts: HCl, sulfate, and crystalline forms
Glucosamine hydrochloride (HCl): this is the most common form in dog supplements, because it is less expensive to produce and contains a higher proportion of glucosamine per gram of salt. Problem: it has limited oral bioavailability (≈ 12% in dogs, Adebowale et al., 2002) and weak clinical results in human medicine.
Glucosamine sulfate: used in human medicine, it has variable bioavailability, but is considered superior to HCl in certain animal models (Meulyzer et al., 2008, horse). However, it is less used in veterinary medicine because the presence of salts (sodium/potassium) may be perceived as a risk in older dogs with comorbidities (heart failure, renal disease).
Glucosamine sulfate cristallin : in Europe, this is a pharmaceutical product with a precise ratio of glucosamine, sulfate, and sodium/chloride ions. Human studies show better clinical efficacy for knee osteoarthritis, probably linked to higher bioavailability (25–44%) (Setnikar & Rovati, 2001; Persiani et al., 2005). Nevertheless, this active ingredient does not exist in veterinary nutrition.
Chondroitin sulfate
Chondroitin is a glycosaminoglycan with a large molecular size, poorly absorbed orally (≈ 5% in dogs, Adebowale et al., 2002). Like glucosamine, it is mainly used in the form of sodium salts.
Bioavailability and synergy of the two molecules
When glucosamine and chondroitin are given together, they appear in the blood within approximately 2 hours after ingestion (Beale, 2004).
However, it is estimated that 10 to 20 times the doses used in vitro are needed to achieve a measurable biological effect in dogs (Comblain et al., 2016).
This gap between theory (useful substrates for cartilage) and pharmacological reality (low absorption, rapid metabolism) is one explanation for the lack of robust clinical efficacy.
Liquid forms vs tablets and chews
A comparative pharmacokinetic study in dogs showed that liquid glucosamine produces a faster plasma peak compared to tablets or chews at an equivalent dose.
This suggests better initial absorption, but no trial has confirmed that this difference translates into a real clinical benefit.
In summary
Glucosamine HCl: the most widely used in veterinary supplements, but the least bioavailable and the least supported by clinical data.
Glucosamine sulfate cristallin: effective in humans, but virtually absent from veterinary products.
Chondroitin sulfate: very limited absorption (≈ 5%), which makes its oral efficacy questionable.
Forme liquide: better absorption profile, but no clinical proof of efficacy.
Even though certain forms (crystalline sulfate, liquid) are better absorbed by the body, clinical data in arthritic dogs remain weak and heterogeneous.
What do clinical trials in dogs show?
A team of researchers from the University of Montreal conducted a systematic review and meta-analysis in 2022 covering 72 clinical trials of dietary supplements for canine and feline osteoarthritis (Barbeau-Grégoire et al., 2022).
The main studies illustrate this trend well:
Moreau et al., 2003 – Among 71 dogs divided across several groups (carprofen, meloxicam, placebo, glucosamine/chondroitin/manganese), no measurable improvement was observed compared to placebo. The doses administered were probably too low, and the presence of other actives (manganese) complicates interpretation.
McCarthy et al., 2007 – In 42 dogs, a slight clinical improvement was reported, sometimes close to that obtained with a non-steroidal anti-inflammatory drug (NSAID). However, the measurements were purely subjective (assessments by veterinarians and owners), without validation by objective tools such as a force plate, a device that precisely measures the force exerted by each paw during walking or running. This tool makes it possible to assess locomotion scientifically, independently of human perception. Here again, the formula tested contained several dietary supplements, making it difficult to attribute the effect.
D’Altilio et al., 2007 – A transient improvement was noted in 20 dogs after 120 days of supplementation, before symptoms returned upon discontinuation. Sample too small, lack of reproducibility, and a multi-active protocol limit any conclusion.
Gupta et al., 2012 – In 40 dogs, owners perceived a reduction in pain by day 90, but no difference was objectively measured in locomotion. Some groups received other actives, including collagen.
Maihasap et al., 2014 – In a post-operative context (cruciate ligament rupture), a slightly better recovery was observed, without a statistically significant difference. The effects are difficult to attribute to the supplement within a natural healing process.
Clinical evidence at a glance
Trop petits effectifs
Short study durations
Non-validated criteria (subjective observations, without standardized tools)
Multi-active formulas: impossible to attribute the effect to glucosamine/chondroitin alone
Variability in doses and forms
Despite a few positive trends, the vast majority of trials fail to show a significant and reproducible benefit for glucosamine and chondroitin in arthritic dogs.
Chondroitin-glucosamine products show a marked lack of efficacy and should no longer be recommended for the treatment of osteoarthritic pain in dogs or cats.
Barbeau-Grégoire et al.
In other words, despite more than 20 years of marketing and popularity, the most robust clinical data conclude that glucosamine and chondroitin do not provide a demonstrated benefit for canine osteoarthritis.
What validated alternatives exist for canine osteoarthritis?
If glucosamine and chondroitin have long been presented as essentials for supporting joints, the available clinical data show that their evidence of efficacy remainsvery limited and inconsistent. La question se pose donc : vers quels actifs se tourner pour un soutien articulaire mieux validé scientifiquement ?
The meta-analysis by Barbeau-Grégoire et al. (2022), which compared all dietary supplements in dogs, clearly highlights two families of actives whose efficacy is most solidly demonstrated:
Omega-3s (EPA and DHA): widely documented, with several independent trials. They reduce joint inflammation and improve mobility, particularly when provided in concentrated and highly bioavailable forms.
L’extrait de green-lipped mussel from New Zealand (Perna canaliculus): naturally rich in Omega-3s but also in antioxidants and other anti-inflammatory molecules. Several clinical studies have shown an improvement in signs of osteoarthritis in dogs.
Omega-3s (EPA/DHA) and New Zealand green-lipped mussel are the actives most supported by the veterinary literature for managing canine osteoarthritis.
Barbeau-Grégoire et al.
By comparison, glucosamine and chondroitin appear as exploratory solutions, with efficacy too uncertain to constitute a first-line option.
Glucosamine and chondroitin have long been considered reference supplements for supporting dogs' joints. But after more than twenty years of clinical trials, the conclusion is clear: the efficacy of these molecules has not been demonstrated in a solid and reproducible manner in arthritic dogs.
The most recent studies confirm a marked lack of efficacy, to the point of no longer recommending these products as a first-line solution.
Conversely, the scientific literature highlights two families of actives with solid evidence:
Omega-3s (EPA/DHA), capable of reducing joint inflammation and improving mobility,
New Zealand green lipped mussel oil, rich in omega-3s and antioxidants, validated by several clinical trials.
It is precisely this dual contribution that makes PERNIXOL® stand out, a liquid supplement developed by Sensilia Laboratory. Formulated from green lipped mussel oil concentrated in Omega-3s and algae oil rich in DHA, it offers scientifically documented joint support, with optimal bioavailability thanks to its liquid form.
Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos. 2002 Sep;23(6):217-25. doi: 10.1002/bdd.315. PMID: 12214321.
Barbeau-Grégoire M, Otis C, Cournoyer A, Moreau M, Lussier B, Troncy E. A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis. Int J Mol Sci. 2022 Sep 8;23(18):10384. doi: 10.3390/ijms231810384. PMID: 36142319; PMCID: PMC9499673.
Beale BS. Use of nutraceuticals and chondroprotectants in osteoarthritic dogs and cats. Vet Clin North Am Small Anim Pract. 2004 Jan;34(1):271-89, viii. doi: 10.1016/j.cvsm.2003.09.008. PMID: 15032132.
Bhathal A, Spryszak M, Louizos C, Frankel G. Glucosamine and chondroitin use in canines for osteoarthritis: A review. Open Vet J. 2017;7(1):36-49. doi: 10.4314/ovj.v7i1.6. Epub 2017 Feb 24. PMID: 28331832; PMCID: PMC5356289.
Comblain F, Serisier S, Barthelemy N, Balligand M, Henrotin Y. Review of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014. J Vet Pharmacol Ther. 2016 Feb;39(1):1-15. doi: 10.1111/jvp.12251. Epub 2015 Jul 23. PMID: 26205697.
D'Altilio M, Peal A, Alvey M, Simms C, Curtsinger A, Gupta RC, Canerdy TD, Goad JT, Bagchi M, Bagchi D. Therapeutic Efficacy and Safety of Undenatured Type II Collagen Singly or in Combination with Glucosamine and Chondroitin in Arthritic Dogs. Toxicol Mech Methods. 2007;17(4):189-96. doi: 10.1080/15376510600910469. PMID: 20020968.
Gupta RC, Canerdy TD, Lindley J, Konemann M, Minniear J, Carroll BA, Hendrick C, Goad JT, Rohde K, Doss R, Bagchi M, Bagchi D. Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. J Anim Physiol Anim Nutr (Berl). 2012 Oct;96(5):770-7. doi: 10.1111/j.1439-0396.2011.01166.x. Epub 2011 May 30. PMID: 21623931.
McCarthy G, O'Donovan J, Jones B, McAllister H, Seed M, Mooney C. Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J. 2007 Jul;174(1):54-61. doi: 10.1016/j.tvjl.2006.02.015. Epub 2006 May 2. PMID: 16647870.
Meulyzer M, Vachon P, Beaudry F, Vinardell T, Richard H, Beauchamp G, Laverty S. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthritis Cartilage. 2008 Sep;16(9):973-9. doi: 10.1016/j.joca.2008.01.006. Epub 2008 Mar 4. PMID: 18295513.
Moreau M, Dupuis J, Bonneau NH, Desnoyers M. Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs with osteoarthritis. Vet Rec. 2003 Mar 15;152(11):323-9. doi: 10.1136/vr.152.11.323. PMID: 12665145.
Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005 Dec;13(12):1041-9. doi: 10.1016/j.joca.2005.07.009. Epub 2005 Sep 13. PMID: 16168682.
Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001 Sep;51(9):699-725. doi: 10.1055/s-0031-1300105. PMID: 11642003.
This article was written by the R&D team at Sensilia Laboratory, experts in animal nutrition.
